miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential
Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Clinical success is suboptimal owing to late diagnosis, limited treatment options, high recurrence rates, and the development of drug resistance. MicroRNAs (miRNAs), a range of small endogenous non-coding RNAs t...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.949566/full |
| _version_ | 1811235088285827072 |
|---|---|
| author | Hang Yan Hang Yan Shengjie Tang Shoujun Tang Jun Zhang Jun Zhang Haiyang Guo Haiyang Guo Chao Qin Chao Qin Haiyang Hu Haiyang Hu Chuan Zhong Li Yang Yunhe Zhu Haining Zhou Haining Zhou Haining Zhou |
| author_facet | Hang Yan Hang Yan Shengjie Tang Shoujun Tang Jun Zhang Jun Zhang Haiyang Guo Haiyang Guo Chao Qin Chao Qin Haiyang Hu Haiyang Hu Chuan Zhong Li Yang Yunhe Zhu Haining Zhou Haining Zhou Haining Zhou |
| author_sort | Hang Yan |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Clinical success is suboptimal owing to late diagnosis, limited treatment options, high recurrence rates, and the development of drug resistance. MicroRNAs (miRNAs), a range of small endogenous non-coding RNAs that are 22 nucleotides in length, have emerged as one of the most important players in cancer initiation and progression in recent decades. Current evidence has revealed the pivotal roles of miRNAs in regulating cell proliferation, migration, invasion, and metastasis in NSCLC. Recently, several studies have demonstrated that miRNAs are strongly associated with resistance to anti-cancer drugs, ranging from traditional chemotherapeutic and immunotherapy drugs to anti-vascular drugs, and even during radiotherapy. In this review, we briefly introduce the mechanism of miRNA dysregulation and resistance to anti-tumor therapy in NSCLC, and summarize the role of miRNAs in the malignant process of NSCLC. We then discuss studies of resistance-related miRNAs in chemotherapy, radiotherapy, targeted therapy, immunotherapy, and anti-vascular therapy in NSCLC. Finally, we will explore the application prospects of miRNA, an emerging small molecule, for future anti-tumor therapy. This review is the first to summarize the latest research progress on miRNAs in anti-cancer drug resistance based on drug classification, and to discuss their potential clinical applications. |
| first_indexed | 2024-04-12T11:46:09Z |
| format | Article |
| id | doaj.art-6345cf85e53641d7a146537805b86690 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T11:46:09Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-6345cf85e53641d7a146537805b866902022-12-22T03:34:21ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.949566949566miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potentialHang Yan0Hang Yan1Shengjie Tang2Shoujun Tang3Jun Zhang4Jun Zhang5Haiyang Guo6Haiyang Guo7Chao Qin8Chao Qin9Haiyang Hu10Haiyang Hu11Chuan Zhong12Li Yang13Yunhe Zhu14Haining Zhou15Haining Zhou16Haining Zhou17Department of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaGraduate School, Institute of Surgery, Zunyi Medical University, Zunyi, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaGraduate School, Institute of Surgery, Zunyi Medical University, Zunyi, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaGraduate School, Institute of Surgery, Chengdu University of TCM, Chengdu, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaGraduate School, Institute of Surgery, Zunyi Medical University, Zunyi, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaGraduate School, Institute of Surgery, Zunyi Medical University, Zunyi, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaDepartment of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining, ChinaGraduate School, Institute of Surgery, Zunyi Medical University, Zunyi, ChinaGraduate School, Institute of Surgery, Chengdu University of TCM, Chengdu, ChinaNon-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Clinical success is suboptimal owing to late diagnosis, limited treatment options, high recurrence rates, and the development of drug resistance. MicroRNAs (miRNAs), a range of small endogenous non-coding RNAs that are 22 nucleotides in length, have emerged as one of the most important players in cancer initiation and progression in recent decades. Current evidence has revealed the pivotal roles of miRNAs in regulating cell proliferation, migration, invasion, and metastasis in NSCLC. Recently, several studies have demonstrated that miRNAs are strongly associated with resistance to anti-cancer drugs, ranging from traditional chemotherapeutic and immunotherapy drugs to anti-vascular drugs, and even during radiotherapy. In this review, we briefly introduce the mechanism of miRNA dysregulation and resistance to anti-tumor therapy in NSCLC, and summarize the role of miRNAs in the malignant process of NSCLC. We then discuss studies of resistance-related miRNAs in chemotherapy, radiotherapy, targeted therapy, immunotherapy, and anti-vascular therapy in NSCLC. Finally, we will explore the application prospects of miRNA, an emerging small molecule, for future anti-tumor therapy. This review is the first to summarize the latest research progress on miRNAs in anti-cancer drug resistance based on drug classification, and to discuss their potential clinical applications.https://www.frontiersin.org/articles/10.3389/fphar.2022.949566/fulldrug resistancemiRNANSCLCtherapybiomarker |
| spellingShingle | Hang Yan Hang Yan Shengjie Tang Shoujun Tang Jun Zhang Jun Zhang Haiyang Guo Haiyang Guo Chao Qin Chao Qin Haiyang Hu Haiyang Hu Chuan Zhong Li Yang Yunhe Zhu Haining Zhou Haining Zhou Haining Zhou miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential Frontiers in Pharmacology drug resistance miRNA NSCLC therapy biomarker |
| title | miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential |
| title_full | miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential |
| title_fullStr | miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential |
| title_full_unstemmed | miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential |
| title_short | miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential |
| title_sort | mirnas in anti cancer drug resistance of non small cell lung cancer recent advances and future potential |
| topic | drug resistance miRNA NSCLC therapy biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.949566/full |
| work_keys_str_mv | AT hangyan mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT hangyan mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT shengjietang mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT shoujuntang mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT junzhang mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT junzhang mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT haiyangguo mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT haiyangguo mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT chaoqin mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT chaoqin mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT haiyanghu mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT haiyanghu mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT chuanzhong mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT liyang mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT yunhezhu mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT hainingzhou mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT hainingzhou mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential AT hainingzhou mirnasinanticancerdrugresistanceofnonsmallcelllungcancerrecentadvancesandfuturepotential |